Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 21 to 30 of 330

TitleReference numberPublishedLast updated
Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitorTA1062
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancerTA1060
Artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway: early value assessmentHTE24
Suspected cancer: recognition and referralNG12
Tislelizumab in combination for untreated advanced non-small-cell lung cancer (terminated appraisal)TA1058
Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapyTA1055
Early and locally advanced breast cancer: diagnosis and managementNG101
Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer (terminated appraisal)TA1052
Atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable (terminated appraisal)TA1047
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resectionTA1043

Results per page

  1. 10
  2. 25
  3. 50
  4. All